I don't know if I like this......
Dendreon Corporation Files Registration Statement for the Public Offering of
2,500,000 Shares of Common Stock
Business Editors/Health & Medical Writers
SEATTLE--(BW HealthWire)--Oct. 11, 2000--Dendreon Corporation
(Nasdaq:DNDN) today announced that it has filed with the Securities
and Exchange Commission a registration statement relating to a
proposed public offering of 2,500,000 shares of common stock.
The offering will be lead-managed by Prudential Vector Healthcare
Group, a unit of Prudential Securities Incorporated, and co-managed by
SG Cowen Securities Corporation and Pacific Growth Equities, Inc.
Dendreon, based in Seattle, Washington, is dedicated to the
discovery and development of novel products for the treatment of
cancer through its innovative manipulation of the immune system.
Dendreon is focused on the development of novel therapeutic vaccines
for the treatment of cancer using proprietary antigen discovery,
antigen engineering and dendritic cell technologies, including a
prostate cancer vaccine, Provenge(TM), which is in Phase III clinical
trials, and a therapeutic vaccines for B-cell malignancies,
Mylovenge(TM), which is in Phase II trials.
A copy of the preliminary prospectus relating to these securities
may be obtained, when available, from Prudential Securities, 111 8th
Avenue, 5th Floor, New York, New York 10011, phone: 212/776-8172,
fax: 212/776-8144.
A registration statement relating to these securities has been
filed with the Securities and Exchange Commission but has not yet
become effective. These securities may not be sold nor may offers to
buy be accepted prior to the time the registration statement becomes
effective. This press release shall not constitute an offer to sell or
a solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under securities laws or any such state or jurisdiction.
--30--AMP/se*
CONTACT: Dendreon Corporation
Martin Simonetti, 206/256-4545 ext. 1500
pr@dendreon.com |
